BillionToOne vs Castle Biosciences
BLLN and CSTL side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BLLN and CSTL compare
BillionToOne is the larger company, worth 4.8 times as much as Castle Biosciences ($5.0B against $1.0B).
BillionToOne grew revenue faster over the last twelve months (71.9% versus 9.8% for Castle Biosciences).
BillionToOne keeps more of each dollar of sales as profit, with a net margin of 11.3% compared with −6.1% at Castle Biosciences.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BLLN | CSTL |
|---|---|---|
| Size and price | ||
| Market cap | $5.0B | $1.0B |
| Share price | $105.15 | $33.79 |
| Change, 1 year | 3.3% | −3.0% |
| Change, 5 years | – | −28.9% |
| Beta (5Y) | −0.04 | 1.38 |
| Employees | 713 | 883 |
| StockData Score | ||
| Total score | 11 | 11 |
| Valuation score | 0 | 2 (better) |
| Growth score | 3 (better) | 2 |
| Performance score | 2 | 3 (better) |
| Health score | 6 (better) | 4 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 11.4× | 2.7× (better) |
| P/B | 8.8× | 2.2× (better) |
| EV/EBITDA | 84.8× | – |
| P/FCF | 146× (better) | 260× |
| FCF yield | 0.68% (better) | 0.38% |
| Fair value | – | $34.71 |
| Margin of safety | – | 2.6% |
| Growth | ||
| Revenue growth (TTM) | 71.9% (better) | 9.8% |
| Revenue growth, 5Y average | – | 40.6% |
| Profitability | ||
| Gross margin | 71.4% | 77.1% (better) |
| Operating margin | 10.2% (better) | −7.4% |
| Net margin | 11.3% (better) | −6.1% |
| FCF margin | 7.8% (better) | 1.1% |
| Return on equity | 30.2% (better) | −4.9% |
| Return on invested capital | – | −11.1% |
| Financial health | ||
| Debt / equity | 0.00 | 0.02 (better) |
| Interest coverage | 1655× (better) | −51.2× |
| Current ratio | 11.25 (better) | 5.28 |
| Altman Z-score | 16.67 (better) | 6.63 |
| Piotroski F-score | 8 (better) | 4 |
| Dividends and buybacks | ||
| Dividend yield | – | 0.00% |
| Years of dividend growth | – | 0 |
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 32.4% | 89.5% |
| Held by insiders | 55.7% | 1.9% |
| Insider net buying, 12 months | −$58.5M | −$18.3M (better) |
| Short interest, % of float | 14.2% | 7.0% |
Go deeper
- BLLN stock overview
- BLLN income statement
- BLLN valuation and score
- CSTL stock overview
- CSTL income statement
- CSTL valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.